Evident Vascular announced today that it closed a Series B financing round to support its AI-powered intravascular ultrasound (IVUS) platform.
The San Jose, California-based company did not disclose the amount raised in the Series B round. It adds to $35 million picked up in a Series A that brought the company out of stealth mode in 2023. Founding investor Vensana Capital contributed to the latest funding round. New investors Shangbay Capital and two undisclosed multinational strategics joined in.
Related: Proscia scoops $50m for AI-driven pathology advancement
Evident Vascular said it plans to use its funds to accelerate the development of its IVUS technology for enhancing vascular imaging. It aims to use the money to support FDA 510(k) clearance of the AI-enabled platform ahead of a U.S. launch.
Cynthia Yee, partner at Vensana Capital, said in a news release that Evident Vascular “is at the forefront of innovation in intravascular imaging that has become the standard of care in peripheral vascular and complex coronary interventions. Yee says the company’s IVUS platform “represents a transformative step forward in vascular care.”
The company hopes to transform vascular imaging through innovations that expand the adoption of IVUS. It aims to increase both the utility and accessibility of IVUS in clinical practice.
“This significant investment underscores our investors’ confidence in Evident Vascular’s mission and technology while highlighting the vital role of intravascular imaging in optimizing patient outcomes, clinical decision-making and procedural success,” said Howard Rosen, CEO and co-founder of Evident Vascular. “We will accelerate our progress toward FDA clearance and further the development of our AI-powered IVUS solution, which aims to set a new standard in vascular image guided therapy.”
Noteworthy players in the IVUS space include Boston Scientific and Novosound, among others.
